Who is a good candidate for ChondroFiller hip injection?

The starting point for most patients is a straightforward question: does my hip damage fall within the range ChondroFiller is designed to address? Two clinical parameters define that range.

Cartilage grade. The formal CE-mark indication requires Outerbridge (ICRS) Grade III or IV damage — meaning partial-thickness fissuring through to full-thickness loss exposing subchondral bone. Grade I or early Grade II surface change, where cartilage structure is largely intact, does not meet the threshold; the scaffold's mechanism depends on a structurally significant defect into which cells can migrate.

Defect size. Published criteria support lesions up to approximately 6 cm² in area. Defects broadly exceeding 2.5 cm in diameter are generally considered too large or uncontained for the injection pathway to fill reliably.

In younger, active patients the most common presentation is anterosuperior acetabular cartilage damage caused by cam-type femoroacetabular impingement (FAI). Where FAI is present, it must be addressed at the same time — leaving the structural cause untreated would undermine the repair environment.

Regarding background joint health: the Mazek 2021 surgical cohort found that patients with Tönnis Grade 2–3 osteoarthritis fared poorly with arthroscopic ChondroFiller placement and were excluded from that series. The ultrasound-guided injection pathway does not carry an equivalent hard rule. For patients with more advanced background wear, the injectable scaffold may still be considered — not as a structural rebuild, but as a protective collagen cushion that reduces friction and supports symptom management. Expectations and goals are framed accordingly at assessment.

None of these parameters translate directly into self-assessment. Candidacy is determined through specialist evaluation, including imaging, to establish defect grade, geometry, and the joint environment into which the scaffold would be placed.

How ChondroFiller forms a repair scaffold inside the hip

Once the liquid reaches the defect, something relatively simple happens: it sets. ChondroFiller is an acellular Type I collagen hydrogel — cell-free, containing no donor cells — and within approximately three to five minutes of contact with the joint environment, it transitions from liquid to a stable three-dimensional gel. That gel conforms to the exact shape of the defect without incision or surgical drying of the joint.

The scaffold's therapeutic work then unfolds over the following weeks through a process called acellular matrix-induced chondrogenesis: the collagen matrix creates a biological environment that draws in the patient's own chondrocytes and progenitor cells from the surrounding tissue. Ex vivo work with human osteochondral specimens has confirmed that active cell migration into the scaffold begins within the first two weeks of contact. The scaffold itself carries no cells — it provides the architecture into which the body's own repair processes can operate.

Over 12 to 24 months, the scaffold gradually biodegrades as native repair tissue progressively replaces it. The aim is to promote endogenous repair rather than to place a permanent implant or filler inside the joint.

ChondroFiller is CE-marked as a Class III medical device across Europe. It does not currently hold FDA approval; patients enquiring from outside Europe should note this regulatory distinction before pursuing the pathway.

Why ultrasound guidance is essential for hip injection

Placing an injection precisely into a focal cartilage defect within the hip demands a level of accuracy that landmark-based technique cannot reliably achieve. The joint lies deep beneath the gluteal musculature and hip flexors — a far less accessible target than the knee or shoulder — and the needle must reach a specific zone within the joint capsule rather than simply entering the joint space in general.

Real-time ultrasound guidance makes that precision achievable in an outpatient clinic setting, without incision, theatre admission, or general anaesthesia. Under continuous imaging, the clinician navigates the needle tip to the defect zone and delivers between 1.0 and 2.3 ml of scaffold material, the exact volume depending on joint dimensions. That precision matters directly: scaffold that disperses into the joint cavity rather than settling into the lesion cannot perform its structural role.

Published access research — including the instrument-technique work of Perez-Carro et al. (PMC8322278) — has documented the particular delivery challenges posed by the hip's tight ball-and-socket geometry and steep acetabular rim. Those findings reinforce why image-guided placement is treated clinically as a requirement for this joint, not an optional refinement.

The in-clinic procedure is conducted under local anaesthesia. No surgical wound, no overnight admission — patients leave the same day.

Outcomes at three to five years: what the evidence shows

The strongest hip-specific data comes from the Mazek 2021 prospective cohort (PMC8460160): 26 patients with acetabular cartilage lesions greater than 2 cm² treated with ChondroFiller during hip arthroscopy, followed for three to five years. Of 21 evaluable patients, 17 — 81% — achieved good or excellent outcomes, with statistically significant cartilage healing confirmed on MRI. Functional improvement was measurable: in that series, patients recorded approximately 30-point gains in modified Harris Hip Score (mHHS), a validated hip-specific measure of pain and daily function, not a marginal statistical shift.

MOCART scoring adds a structural dimension to these results. Assessed by MRI at one year, MOCART scores across published ChondroFiller cohorts fall between 70 and 87 out of 100 — indicating meaningful defect filling and scaffold integration beyond symptomatic change alone.

For broader context, the hip findings sit within a consistent pattern across other joint applications. Published cohorts covering knee, hip, and small-joint treatments report 70 to 85% of patients achieving meaningful symptom relief. Knee-specific data show IKDC gains of approximately 30 points over 12 to 36 months — a functional improvement comparable in magnitude to the hip mHHS data, though the two scores assess different joints and different patient groups. These figures provide supporting context; they do not substitute for the hip-specific evidence from Mazek 2021.

Across published series, the complication rate is reported at approximately 0.06%, consistent with the product's CE-mark safety profile.

Evidence gaps patients should know about

Three honest limitations shape how the available evidence should be read.

First, no large-scale randomised controlled trial has evaluated ChondroFiller in the hip. The evidence base — including the Mazek 2021 cohort (PMC8460160) — rests on prospective observational series, some with manufacturer involvement in study design or funding. That is the current state of the field, not a deficiency unique to this product.

Second, most published trials used arthroscopic surgical delivery. The ultrasound-guided injection pathway — the route used in outpatient practice — has fewer standalone hip-specific outcome studies. Extrapolating from arthroscopic series to the injection route involves a degree of clinical judgement; the gap between published evidence and current practice is real, and patients should understand it as such.

Third, histological data confirming whether repair tissue is true hyaline cartilage or the more common fibrocartilage remains limited beyond five years. The functional gains documented at three to five years are genuine, but what the repaired tissue looks like at a cellular level over longer horizons is not yet established.

Set against this, the prospective data across cohorts are internally consistent, and the reported complication rate of approximately 0.06% is reassuringly low. The evidence falls short of the RCT standard — but it is coherent, and the safety profile is well-characterised.

Getting assessed at London Cartilage Clinic

The five preceding sections lay out the clinical logic — but reading about ChondroFiller is not the same as knowing whether it applies to your particular hip. That question can only be answered through direct assessment.

A consultation at London Cartilage Clinic is structured around that determination. It typically involves clinical history and examination, review of any existing imaging, and — where needed — diagnostic ultrasound or MRI to characterise defect grade, size, and the condition of the surrounding joint. The outcome of that appointment is a clearly explained candidacy decision: whether the injection pathway is appropriate, whether a combination approach makes sense, or whether the pattern of damage points more toward a surgical or conservative route. There is no presumption of treatment going in.

Professor Paul Y. F. Lee leads specialist cartilage assessment at the Harley Street clinic, with particular focus on focal defect management across the hip and other joints. For patients based outside London, the MSK Doctors group's Lincolnshire and Grantham sites offer an alternative access point for the same assessment pathway.

To arrange an initial assessment, visit londoncartilage.com.